Cargando…

Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis

BACKGROUND: The choice of treatment in patients with metastatic colorectal cancer (mCRC) is generally influenced by tumour and patient characteristics, treatment efficacy and tolerability, and quality of life. Better patient selection might lead to improved outcomes. METHODS: This post hoc explorato...

Descripción completa

Detalles Bibliográficos
Autores principales: Tabernero, Josep, Argiles, Guillem, Sobrero, Alberto F, Borg, Christophe, Ohtsu, Atsushi, Mayer, Robert J, Vidot, Loick, Moreno Vera, Shanti R, Van Cutsem, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7440836/
https://www.ncbi.nlm.nih.gov/pubmed/32817131
http://dx.doi.org/10.1136/esmoopen-2020-000752
_version_ 1783573191593033728
author Tabernero, Josep
Argiles, Guillem
Sobrero, Alberto F
Borg, Christophe
Ohtsu, Atsushi
Mayer, Robert J
Vidot, Loick
Moreno Vera, Shanti R
Van Cutsem, Eric
author_facet Tabernero, Josep
Argiles, Guillem
Sobrero, Alberto F
Borg, Christophe
Ohtsu, Atsushi
Mayer, Robert J
Vidot, Loick
Moreno Vera, Shanti R
Van Cutsem, Eric
author_sort Tabernero, Josep
collection PubMed
description BACKGROUND: The choice of treatment in patients with metastatic colorectal cancer (mCRC) is generally influenced by tumour and patient characteristics, treatment efficacy and tolerability, and quality of life. Better patient selection might lead to improved outcomes. METHODS: This post hoc exploratory analysis examined the effect of prognostic factors on outcomes in the Randomized, Double-blind, Phase 3 Study of trifluridine tipiracil (FTD/TPI) plus Best Supportive Care (BSC) versus Placebo plus BSC in Patients with mCRC Refractory to Standard Chemotherapies (RECOURSE) trial. Patients were redivided by prognosis into two subgroups: those with <3 metastatic sites at randomisation (low tumour burden) and ≥18 months from diagnosis of metastatic disease to randomisation (indolent disease) were included in the good prognostic characteristics (GPC) subgroup; the remaining patients were considered to have poor prognostic characteristics (PPC). RESULTS: GPC patients (n=386) had improved outcome versus PPC patients (n=414) in both the trifluridine/tipiracil and placebo arms. GPC patients receiving trifluridine/tipiracil (n=261) had an improved median overall survival (9.3 vs 5.3 months; HR (95% CI) 0.46 (0.37 to 0.57), p<0.0001) and progression-free survival (3.3 vs 1.9 months; HR (95% CI) 0.56 (0.46 to 0.67), p<0.0001) than PPC patients receiving trifluridine/tipiracil (n=273). Improvements in survival were irrespective of age, Eastern Cooperative Oncology Group Performance Status (ECOG PS), KRAS mutational status, and site of metastases at randomisation. In the trifluridine/tipiracil arm, time to deterioration of ECOG PS to ≥2 and proportion of patients with PS=0–1 discontinuing treatment were longer for GPC than for PPC patients (7.8 vs 4.2 months and 89.1% vs 78.4%, respectively). CONCLUSION: Low tumour burden and indolent disease were factors of good prognosis in late-line mCRC, with patients experiencing longer progression-free survival and greater overall survival.
format Online
Article
Text
id pubmed-7440836
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-74408362020-08-28 Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis Tabernero, Josep Argiles, Guillem Sobrero, Alberto F Borg, Christophe Ohtsu, Atsushi Mayer, Robert J Vidot, Loick Moreno Vera, Shanti R Van Cutsem, Eric ESMO Open Original Research BACKGROUND: The choice of treatment in patients with metastatic colorectal cancer (mCRC) is generally influenced by tumour and patient characteristics, treatment efficacy and tolerability, and quality of life. Better patient selection might lead to improved outcomes. METHODS: This post hoc exploratory analysis examined the effect of prognostic factors on outcomes in the Randomized, Double-blind, Phase 3 Study of trifluridine tipiracil (FTD/TPI) plus Best Supportive Care (BSC) versus Placebo plus BSC in Patients with mCRC Refractory to Standard Chemotherapies (RECOURSE) trial. Patients were redivided by prognosis into two subgroups: those with <3 metastatic sites at randomisation (low tumour burden) and ≥18 months from diagnosis of metastatic disease to randomisation (indolent disease) were included in the good prognostic characteristics (GPC) subgroup; the remaining patients were considered to have poor prognostic characteristics (PPC). RESULTS: GPC patients (n=386) had improved outcome versus PPC patients (n=414) in both the trifluridine/tipiracil and placebo arms. GPC patients receiving trifluridine/tipiracil (n=261) had an improved median overall survival (9.3 vs 5.3 months; HR (95% CI) 0.46 (0.37 to 0.57), p<0.0001) and progression-free survival (3.3 vs 1.9 months; HR (95% CI) 0.56 (0.46 to 0.67), p<0.0001) than PPC patients receiving trifluridine/tipiracil (n=273). Improvements in survival were irrespective of age, Eastern Cooperative Oncology Group Performance Status (ECOG PS), KRAS mutational status, and site of metastases at randomisation. In the trifluridine/tipiracil arm, time to deterioration of ECOG PS to ≥2 and proportion of patients with PS=0–1 discontinuing treatment were longer for GPC than for PPC patients (7.8 vs 4.2 months and 89.1% vs 78.4%, respectively). CONCLUSION: Low tumour burden and indolent disease were factors of good prognosis in late-line mCRC, with patients experiencing longer progression-free survival and greater overall survival. BMJ Publishing Group 2020-08-19 /pmc/articles/PMC7440836/ /pubmed/32817131 http://dx.doi.org/10.1136/esmoopen-2020-000752 Text en © Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made are indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Original Research
Tabernero, Josep
Argiles, Guillem
Sobrero, Alberto F
Borg, Christophe
Ohtsu, Atsushi
Mayer, Robert J
Vidot, Loick
Moreno Vera, Shanti R
Van Cutsem, Eric
Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis
title Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis
title_full Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis
title_fullStr Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis
title_full_unstemmed Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis
title_short Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis
title_sort effect of trifluridine/tipiracil in patients treated in recourse by prognostic factors at baseline: an exploratory analysis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7440836/
https://www.ncbi.nlm.nih.gov/pubmed/32817131
http://dx.doi.org/10.1136/esmoopen-2020-000752
work_keys_str_mv AT tabernerojosep effectoftrifluridinetipiracilinpatientstreatedinrecoursebyprognosticfactorsatbaselineanexploratoryanalysis
AT argilesguillem effectoftrifluridinetipiracilinpatientstreatedinrecoursebyprognosticfactorsatbaselineanexploratoryanalysis
AT sobreroalbertof effectoftrifluridinetipiracilinpatientstreatedinrecoursebyprognosticfactorsatbaselineanexploratoryanalysis
AT borgchristophe effectoftrifluridinetipiracilinpatientstreatedinrecoursebyprognosticfactorsatbaselineanexploratoryanalysis
AT ohtsuatsushi effectoftrifluridinetipiracilinpatientstreatedinrecoursebyprognosticfactorsatbaselineanexploratoryanalysis
AT mayerrobertj effectoftrifluridinetipiracilinpatientstreatedinrecoursebyprognosticfactorsatbaselineanexploratoryanalysis
AT vidotloick effectoftrifluridinetipiracilinpatientstreatedinrecoursebyprognosticfactorsatbaselineanexploratoryanalysis
AT morenoverashantir effectoftrifluridinetipiracilinpatientstreatedinrecoursebyprognosticfactorsatbaselineanexploratoryanalysis
AT vancutsemeric effectoftrifluridinetipiracilinpatientstreatedinrecoursebyprognosticfactorsatbaselineanexploratoryanalysis